Evommune Announces First Patient Dosed In Phase 2b Trial Of EVO756 For Migraine Prevention, Enrolling Approximately 330 Patients; Top-Line Data Expected In 2027

뉴스 본문을 불러오고 있어요.

Evommune Announces First Patient Dosed In Phase 2b Trial Of EVO756 For Migraine Prevention, Enrolling Approximately 330 Patients; Top-Line Data Expected In 2027 | 웨이프 WAPE

Evommune Announces First Patient Dosed In Phase 2b Trial Of EVO756 For Migraine Prevention, Enrolling Approximately 330 Patients; Top-Line Data Expected In 2027

기사 요약

관련 종목

댓글 —